首页 文献索引 SCI期刊 AI助手
期刊目录筛选

期刊名:Japanese journal of cancer and chemotherapy

缩写:

ISSN:0385-0684

e-ISSN:

IF/分区:0.0/

文章目录 更多期刊信息

共收录本刊相关文章索引22431
Clinical Trial Case Reports Meta-Analysis RCT Review Systematic Review
Classical Article Case Reports Clinical Study Clinical Trial Clinical Trial Protocol Comment Comparative Study Editorial Guideline Letter Meta-Analysis Multicenter Study Observational Study Randomized Controlled Trial Review Systematic Review
Kanetaka Maeshiro,Yoshiki Chinen,Kouji Yoshikawa et al. Kanetaka Maeshiro et al.
A 66-year-old woman presented with multiple nodular lesions of approximately 5 mm in the bilateral lower lobes on computed tomography during a close examination for gastric cancer and a left renal tumor. Because a pathological diagnosis of ...
Fumio Yamazaki,Yoshiyuki Saegusa,Munemitsu Kobayashi et al. Fumio Yamazaki et al.
Chemotherapy is the standard treatment for patients with stage Ⅳ colorectal cancer. However, some patients are unable to continue standard chemotherapy because of adverse side effects, while others decline this treatment option to maintain...
Yasutaka Sumi,Yuki Yasutaka,Kentaro Ogata et al. Yasutaka Sumi et al.
Background: Hematologic malignancies have shown improved prognosis in some diseases owing to advanced treatment. Cytarabine (Ara-C) is widely used for treatment; however, ocular symptoms frequently occur as a side effect....
Momoka Inoue,Kokoro Ijima,Mika Kurihara et al. Momoka Inoue et al.
Opioid‒induced constipation (OIC) occurs in 60-90% of patients with cancer and can lead to a decline in their quality of life. Naldemedine tosilate tablets (NAL), approved in 2017, improves OIC by specifically binding to the μ-opioid rece...
Toshio Suzuki Toshio Suzuki
Between 2024 and early 2026, HER2-directed oncology has rapidly evolved from a strategy confined to HER2-overexpressing malignancies to a histology-agnostic framework that accommodates diverse HER2 alterations, including amplification/overe...
Yoichi Naito Yoichi Naito
BRAF is a serine/threonine kinase that functions as a key component of the RAS/RAF/MEK/ERK (MAPK) signaling pathway and is recognized as an important oncogenic driver across multiple cancers. BRAF mutations are detected in a variety of mali...
Toshio Kokuryo,Takashi Mizuno,Shunsuke Onoe et al. Toshio Kokuryo et al.
Fibroblast growth factor receptors (FGFR) are tyrosine kinases that regulate cellular responses including proliferation, survival, and migration. FGFR fusion genes arose from chromosomal translocations or deletions, lead to ligand-independe...
Kenji Kawada Kenji Kawada
Selpercatinib, a RET inhibitor, is covered by insurance for all solid tumors that are positive for the RET fusion gene. The RET fusion gene is positive in 2% of lung cancers and 10-20% of papillary thyroid cancers. In other solid tumors, po...
Nobuyuki Kakiuchi Nobuyuki Kakiuchi
Cancer originates from a single ancestor cell that acquires driver mutations, which confer a selective growth advantage, followed by the acquisition of additional driver mutations by descendant cells. Recently, it has become evident that so...
Jyunta Hayashi,Kiichi Sugimoto,Saki Kochi et al. Jyunta Hayashi et al.
In recent years, the efficacy of preoperative treatment for locally advanced colorectal cancer has been reported to improve surgical cure rates and decrease postoperative recurrence rates. In this study, we report a case of locally advanced...